ArticleCell communication and signaling : CCS2025
Uncovering functional divergence and cellular clusters with specific gene signatures in HNSCC clonal spheroids.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Uncovering the Potential of 3D Spheroids for Modeling the Cellular Crosstalk Within the Tumor Microenvironment in HNSCC.Biotechnology journal · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Head and neck squamous cell carcinoma (HNSCC) exhibits substantial genetic and functional heterogeneities. We generated clonal spheroids (CS) from HNSCC cell lines and patient tumor cells, uncovering distinct functional differences. Hyperproliferative spheroids (HRPS) showed increased proliferation and tumorigenic potential, whereas hypoproliferative spheroids (HOPS) demonstrated enhanced migration and resistance to cisplatin and radiation. In patient tumor-derived spheroids, spheroid size distribution analysis across various TNM stages indicated that early-stage tumors (T2N0M0) predominantly formed HRPS, while later-stage tumors (T4N2M0) exhibited a higher prevalence of HOPS. Single-cell RNA sequencing (scRNA-seq) identified six clusters in the HOPS and four in the HRPS, each defined by unique gene expression profiles and pathway enrichment. HOPS were enriched with fibroblast, mesenchymal, and keratinizing epithelial cells, indicating a metastatic phenotype. They also expressed genes associated with stemness (KRT15 and ALDH3A1). Conversely, HRPS was characterized by proliferative genes, including TOP2A, AURKA, CKS2, AREG, and ANLN, suggesting an advanced HNSCC proliferative signature. Despite being generated from only two cells/well, the various clusters in both spheroid types mirrored the diverse tumor microenvironment in HNSCC, including neoplastic, epithelial, basal, fibroblast, and mesenchymal cells. Notably, the gene expression profiles of Cluster 3 in the HOPS and Cluster 1 in the HRPS closely matched the expression patterns observed in the HNSCC-TCGA dataset. These clusters also displayed a high transcriptional correlation between patient tumors and their xenografts, reinforcing the clonal nature of HNSCC's genetic and functional diversity of HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.